Dupilumab treatment normalizes skin barrier function in children aged 6-11 years with moderate-to-severe atopic dermatitis

被引：0
|
作者：
Cork, Michael J. [1 ]
Leung, Donald [2 ]
Ong, Peck [3 ]
Danby, Simon [1 ]
Ramirez-Gama, Marco [2 ]
Garcia, Shannon [2 ]
Patricia, Taylor [2 ]
Byers, Rob [1 ]
Matcher, Stephen [1 ]
Zahn, Joseph [4 ]
Bologna, Gabriel [5 ]
Zhang, Annie [6 ]
机构：
[1] Univ Sheffield, Sheffield Dermatol Res, Sheffield, England
[2] Natl Jewish Hlth, Denver, CO USA
[3] Univ Southern Calif, Childrens Hosp Los Angeles, Los Angeles, CA USA
[4] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[5] Ividata Life Sci, Levallois Perret, France
[6] Sanofi, Cambridge, MA USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
D O I：
10.1093/bjd/ljae090.063
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P036
引用
收藏
页码：I30 / I30
页数：1
相关论文
共 50 条
  • [31] Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to < 6 years with moderate-to-severe atopic dermatitis
    Paller, A. S.
    Guttman-Yassky, E.
    Boguniewicz, M.
    Sun, Y.
    Wolfe, K.
    Kroeller-Schoen, S.
    ALLERGOLOGIE, 2022, 45 (08) : 621 - 622
  • [32] Hematologic laboratory parameters in adults and children aged 6 months to 18 years with moderate-to-severe atopic dermatitis treated with dupilumab
    Paller, Amy S.
    Siegfried, Elaine C.
    Khokhar, Faisal A.
    Gonzalez, Tayler
    ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (06) : 567 - 567
  • [33] Dupilumab Reduces Inflammatory Biomarkers in Patients Aged 6 Months to 18 Years With Moderate-to-Severe or Severe Atopic Dermatitis
    Beck, Lisa
    Muraro, Antonella
    Boguniewicz, Mark
    Chen, Zhen
    Levit, Noah
    Marco, Ainara Rodriguez
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB152 - AB152
  • [34] Dupilumab treatment restores skin barrier function measured by transepidermal water loss in adults and adolescents with moderate-to-severe atopic dermatitis
    Bissonnette, R.
    Ramirez-Gama, M.
    Garcia, S.
    Taylor, P.
    Praestgaard, A.
    Levit, N. A.
    Rossi, A. B.
    Zhang, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E156 - E156
  • [35] Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis
    James E. Frampton
    Hannah A. Blair
    American Journal of Clinical Dermatology, 2018, 19 : 617 - 624
  • [36] Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis
    Frampton, James E.
    Blair, Hannah A.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (04) : 617 - 624
  • [37] Dupilumab treatment leads to mild transient increases in eosinophil levels without clinical relevance in children aged 6-11 years with severe atopic dermatitis
    Paller, Amy
    Wollenberg, Andreas
    Cork, Michael
    Siegfried, Elaine
    Chen, Zhen
    Vakil, Jignesh
    Levit, Noah
    Marco, Ainara Rodriguez
    Radwan, Amr
    CLINICAL AND EXPERIMENTAL ALLERGY, 2021, 51 (12): : 1687 - 1688
  • [38] Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to &lt; 6 years with moderate-to-severe atopic dermatitis
    Paller, A.
    Guttman-Yassky, E.
    Boguniewicz, M.
    Sun, Y.
    Wolfe, K.
    Dillon, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : S51 - S51
  • [39] Dupilumab treatment improves health-related quality of life in children aged 6 months-5 years with moderate-to-severe atopic dermatitis
    Paller, Amy S.
    Simpson, Eric L.
    Siegfried, Elaine C.
    Cork, Michael J.
    Wollenberg, Andreas
    Arkwright, Peter D.
    Zhang, Haixin
    Wang, Zhixiao
    Rodriguez Marco, Ainara
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E104 - E105
  • [40] DUPILUMAB REDUCES BIOMARKERS INDICATIVE OF TYPE 2 INFLAMMATION IN CHILDREN AGED 6 MONTHS TO 5 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Paller, Amy S.
    Flohr, Carsten
    Guttman-Yassky, Emma
    Boguniewicz, Mark
    Wipperman, Matthew F.
    Rodriguez Marco, Ainara
    Wolfe, Kelley
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 30 - 31
12345